Name

Position

Affiliation

Country

Comment

Martin Paparella

Senior Researcher

Medical University Innsbruck

Austria

Bernard GODELLE

University professor

University of Montpellier

France

Penny Nymark

Assistant Professor

Karolinska Institutet

Sweden

In parallel with development of non-animal methods, known as New Approach Methodologies (NAMs) within chemical risk assessment, it is also paramount that all generated data in science is made Findable, Accessible, Interoperable and Reusable (FAIR)! Besides being a non-animal method in itself, reuse of data is the only way we can move into an era of machine-driven and AI-supported predictive chemical risk assessment without the reliance on animal testing.

Pranjul Shah

Head of the Incubator

University of Luxembourg

Luxembourg

Mario Rothbauer

Group Leader

Medical University of Vienna - Dpt. Ortho Trauma Surgery

Austria

Dania Movia

Assistant Professor

Trinity College Dublin

Republic of Ireland

Prof. Dr. Stefan Dübel

Head, Dept. of Biotechnology

Technische Universität Braunschweig

Germany

Ashwani Sharma

Co-founder

Insight Biosolutions

France

Hello, I agree that we need alternative methods than animal testing as using like human in vitro models can give better results than animal testing.

Janneke Hogervorst, PhD

Postdoctoral researcher

Hasselt University

Belgium

For many areas of research, animal testing is known to have very limited validity. We don't need to first develop non-animal methods there; we should just end animal experiments there right now and spend our limited resources on other research. We need more systematic reviews into the validity of animal experiments, rather than treat animal experiments as the gold standard that we need to find replacements for. Ending what doesn't work is innovation too.

Love Hansell

PhD Researcher

Radboud University

Sweden

Bas van Balkom

Asst Professor

UMC Utrecht

The Netherlands

Margherita Scarpa

Engeneer

Institut Jacques Monod

France

Federica Emiliani

Lecturer

InHolland University of Applied Sciences

The Netherlands

Investing even more in in vitro/silico modelling

Birgit Goversen

Postdoctoral researcher

Amsterdam UMC

The Netherlands

- More funds for the improvement of current NAMs

- A focus on understanding, supporting and convincing stakeholders; not on forcing them to use NAMs

Merel Ritskes-Hoitinga

Prof. in Evidence-Based Transition to Animal-Free Innovations

Utrecht University

The Netherlands

Setting goals is key, just like we do for the economy. The science and technology ARE here to move to non-animal science. By teaming up with social sciences and key stakeholders we can accelerate and strive towards ending animal testing by 2035.

Rosalinde Masereeuw

Full professor

Utrecht University

The Netherlands

Make sure everybody is on-board, we can only make the transition together.

Mathieu Vinken

ONTOX coordinator/university professor

Vrije Universiteit Brussel

Belgium

Koen Kramer

Researcher animal ethics

Wageningen University & Research

The Netherlands

AC van Veen

Postdoc

Radboud University

The Netherlands

Tuula Heinonen

Professor

Tampere University

Finland

Regulators give acceptance criteria for approving non-animal methods to predict safety (all chemicals) for all end points and efficacy (drugs)

Julia D Zajac

Project manager

Vrije Universiteit Brussel

Belgium

Sonja von Aulock

Editor in chief, CEO

ALTEX - Alternatives to Animal Experimentation

Germany

Tobias Theska

PhD Student

Max Planck Institute for Biology Tübingen

Germany

Ingeborg Eva Reihs

Doctoral candidate

Medical University of Vienna

Austria

More specific funding for absolute animal-free and clean science, method establishment. Awards for absolute animal-free approaches and more critical thinking about so-called animal-free research.

Alicia Paini

Senior Toxicologist

esqLABS GmbH

Italy

Eliska Kuchovska

postdoctoral researcher

IUF - Leibniz Research Institute for Environmental Medicine

Germany

Marina Garcia de Lomana

Research Scientist

Bayer AG

Germany

Job Berkhout

PhD Student

UU, RIVM

The Netherlands

Domenico Gadaleta

Scientific Consultant

Istituto di Ricerche Farmacologiche Mario Negri - IRCCS

Italy

Katharina Koch

Postdoctoral Researcher

IUF - Leibniz-Research Institute for Environmental Medicine

Germany

More interaction between researchers, the regulatory bodies and the industry. ECHA for example! More case studies supported by the regulatory bodies and indurtry. More guidance on the use of PBTK in POD estimation.

Erwin L Roggen

CEO and WP6 leader of the ONTOX project

3Rs Management and Consulting ApS

Denmark

Willingness to change and courage to embrace innovation in practice, not only words.

Ellen Fritsche

Professor

DNTOX GmbH

Germany

Establish case studies involving different stakeholders and compare classical risk assessment to NAM-based risk assessment.

Helena Kandarova

ESTIV President, Director of UEFT CEM SAS

ESTIV and Slovak Academy of Science

Slovakia

Please try to harmonize legistlation accorst various sectors so that animal testing is not requested in areas, where replacements are availabe (e.g. medical devices, pesticides, pharmaceuticals)

Alessio Gamba

Postdoc researcher

VPH institute and University of Liege

Belgium

Jeffrey Bajramovic

Director 3Rs Centre Utrecht

Utrecht University

The Netherlands

PD Dr.-Ing. Joachim Wiest

Adjunct professor

Technical University of Munich

Germany

Nicolas Bayer

Master Student

RPTU Kaiserslautern

Germany

ethically based funding!!!

Christiane Spruck

PhD student

IUF

Germany

Florian Caiment

Associate Professor

Maastricht University

The Netherlands

Andreas Schiwy

PostDoc, Teamleader

Goethe University

Germany

The advancement of chemical defined media for culture of cells, replacement of animal derived products like fetal bovine serum as well as rat liver S9 with biotechnological alternatives. The development of physiological media to sustain cell lines that show similar reaction compared to the human body.

Liliana Moreira Teixeira

Assistant professor

University of Twente

The Netherlands

busuqet

ceo

altertox

Belgium

John Grin

Full professor in the governance of transitions

University of Amsterdam

The Netherlands

Huub Schellekens

Emeritus Professor

Utrecht University

The Netherlands

Esther Wenzel

COO

Abcalis GmbH

Germany

Tamara Vanhaecke

Professor

Vrije Universiteit Brussel, Faculty of Medicine & Pharmacy

Belgium

Maria Tsamou

Chief Scientific Officer

ToxGenSolutions

The Netherlands

Emilio Benfenati

Head of Department

Istituto di Ricerche Farmacologiche Mario Negri

Italy

Wouter Dhert

Professor and Scientific Director Innovation in Life Sciences

Utrecht University

The Netherlands

Daniela Salvatori

Professsor Anatomy and Physiology, Chairperson Animal-free Innovation Utrecht University

Utrecht University

The Netherlands

Education (interprofessioanl education) and creation of a community able to go through the necessary changes

Hanna Dusza

Postdoctoral researcher

Utrecht University

The Netherlands

Annalisa Gastaldello

Project Officer

European Commission

Italy

Konstantina

PhD student

VU Amsterdam

The Netherlands

Allocating funds to research aimed at developing in vitro methods modeling animal testing.

Jakob (Jaap) Heringa

Professor Bioinformatics

Vrije Universiteit Amsterdam

The Netherlands

FAIR data infrastructure; Digital twin

Jos Joore

CEO

Mimetas

The Netherlands

Victoria Marincheva

Assist. Prof.

University of Forestry Sofia

Bulgaria

Iliyan Manev

Assos. Prof. in Immunology

Faculty of Veterinary medicine, University of Forestry

Bulgaria

Eckhard von Keutz

Consultant

Independent

Germany

A concrete working plan which contains the deliverables and the associated timelines. Leadership and commitment are needed to execute on the roadmap.

Jiayi Yang

PhD candidate

Utrecht University

The Netherlands

Silvia Scaglione

Chief Scientist, President of React4life

React4life

Italy

Kamile Jovaisaite

Scientific Sales Representative

STEMCELL Technologies

The Netherlands

Madalena Cipriano

Senior Scientist

University of Tübingen

Germany

Benoît Maisonneuve

CSO

NETRI

France

4 steps are necessary IMO: 1 - funding to develop and validate NAMs with clinical data, 2 - access to the clinical data (usually confidential), 3 - a regulatory framework to develop NAMs, and of course 4 - a legislative evolution of the European regulation (concerning drug developement etc) similar to what has been done in the USA and in India.

Luiz Ladeira

Postdoctoral researcher

Liège Université

Belgium

Erwin L Roggen

CEO

ToxGenSolutions BV

The Netherlands

Wiilingness and confidence based on scientific data in stead of believe.

Eva Bernet Kempers

postdoctoral researcher

University of Antwerp

Belgium

Line Mathiesen

Associate Professor

University of Copenhagen

Denmark

Ellen Fritsche

Prof.

IUF

Germany

Costanza Rovida

Scientific Officer

CAAT-Europe

Germany

Christian Maass

Principal Scientist, Lead Digital Organ-on-Chip Platform

esqLABS

Germany

Coordination with roadmap on standardization from CEN/CENELEC

Timea Gandek

Phd student

University of Groningen

The Netherlands

Ramiro Jover

Professor

University of Valencia

España

Kathrin Herrmann

Senior Associate

Johns Hopkins University Center for Alternatives to Animal Testing (CAAT)

Germany

Rafael Gozalbes

CEO

ProtoQSAR SL

SPAIN

Arno Gutleb

Managing Director

INVITROLIZE sarl

Luxembourg

Matthias Gossmann

CEO

innoVitro GmbH

Germany

Catarina Custódio

CEO

Metatissue

Portugal

Philippe Vanparys

Retired scientist

Consultant

Belgium

Marianna Norring

Researcher

University of Helsinki

Finland

Ariel Mörtengren

Developer

Masters degree in pharmacy

Finland

Hanna Vuorenpää

Postdoctoral Research Fellow

Tampere University

Finland

I would like to highlight the need for targeted funding for academic society with a clear message on investment on non-animal approaches across different disciplines.

Jasper van Berkel

COO

Orgonex

The Netherlands

Organoids should replace animal testing

Marta Tafalla

Senior Lecturer

Universitat Autònoma de Barcelona

Spain

Montserrat Escartin

Full professor

Universitat de Girona

Spain

Catia Faria

Assistant Professor Moral Philosophy

Complutense University of Madrid

Spain

Núria Almiron

Professor

Universitat Pompeu Fabra

Spain

jose ALbelda

Profesor Titular de Universidad

UPV

España

Cristian Moyano

Postdoctoral researcher

Universitat Autònoma de Barcelona

Spain

Vito D'Alessandro

PhD Student

Università del Salento

Italy

Lorena Rodríguez Mattalía

Profesora titular de universidad

Universidad Politécnica de Valencia

España

Asunción Herrera

Profesora Titular Filosofía Moral

Universidad de Oviedo

España

Paula Casal

Professor

ICREA and at Pompeu Fabra University

Spain

Start with banning any research which is not essential to tackle serious health problems, seek alternatives for the latter, and in the meantime maximally improve improve the conditions for animals, and stop killing the control group. To maximize adoptions of control group animals, ban their breeding for the companion animal industry.

Sara Martín

Senior Lecturer

Universitat Autònoma de Barcelona

Spain

Obviously, the use of AI to simulate real-life experiments as approximately as possible

Angélica Velasco

Phd professor of moral philosophy

University of Valladolid

Spain

Jorge Riechmann

Profesor titular de Filosofía moral

Departamento de Filosofía de la Universidad Autónoma de Madrid

España

Lucia Milec

Project Manager

Slovak Academy of Sciences

Slovakia

Laura Fernández

Postdoctoral Researcher

University of Barcelona / UPF-Centre for Animal Ethics

Spain

Pilar Medina-Bravo

Senior Lecturer

Universitat Pompeu Fabra

Spain

Marine Lercier

Predoctoral Researcher and PhD Candidate in Animal Law

Autonomous University of Barcelona

Spain

Miquel Rodrigo-Alsina

Full Professor

Universitat Pompeu Fabra

Spain

Priscila Alvarez Cueva

Profesora contratada doctor

Universidad Internacional de Valencia

España

Anna Wijen

PhD student

Maastricht University

The Netherlands

María Ruiz Carreras

Lecturer

Lund University

Sweden

Xavier Martinez Lacasa

Medieval doctor

Internal Medicine

Spain

Gemma Arca

Neonatologa

Hospital Clinic Barcelona

Spain

Paola Dolader

Consultant

Vall d’hebrob

Spain

LUIS FALCON

PRESIDENT

GNU SOLIDARIO

SPAIN

Nikolas Gaio

CTO

BIOND Solutions

The Netherlands

Kristie O’Neill

Senior Researcher

Radboud University

The Netherlands

Chrysafis Andreou

Assistant Professor

University of Cyprus

Cyprus

Giel Hendriks

CEO

Toxys

The Netherlands

Make funding available for SMEs to validate new methods.

Hossein Eslami Amirabadi

Managing Director

AZAR Innovations

The Netherlands

Venetia Karamitsou

Postdoc

Sanofi

Greece

Peter J. Boogaard

Professor of Environmental Health

Wageningen University and Research

Netherlands

Marco Corvaro

Technical Team Leader, Regulatory Toxicology

Corteva Agriscience Italia S.r.l.

Italy

Niek Rijnveld

CEO

Optics11 Life

Netherlands

L. Cornips

Senior-researcher

NL-Lab (KNAW) & Maastricht University

The Netherlands

Sergio martínez mesón

Researcher

Instituto Catalán de Antropología

Spain

Surama Lázaro

PhD student

UNED

Spain

Simona Marzorati

Project Manager

NanoPhoria Srl

Italy

PJ Beers

Senior Researcher

Dutch Research Institute for Transitions

The Netherlands

Cyrille Krul

Professor Innovative Testing in Life Sciences & Chemistry

Utrecht University of Applied Sciences

The Netherlands

Iva Sovadinova

Academic researcher

Masaryk University, Faculty of Science, RECETOX

Czechia

Astrid Murumägi

Senior Researcher

University of Helsinki

Finland

Daniela Ungureanu

Assoc. Prof.

University of Helsinki

Finland

Delia Elena Diaconasu

Researcher

Alexandru Ioan Cuza University of Iasi

Romania

Harlan Barker

PhD Student

Tampere University

Finland

Alice Dini

Doctoral Researcher

University of Oulu

Finland

Carmen Madorrán Ayerra

Assistant Professor

Universidad Autónoma de Madrid

Spain

Anja Krippner-Heidenreich

Senior Research Scientist

Princess Maxima Centrum for Childhood Cancer

The Netherlands

Hubert Dirven

Department Director Chemical toxicology

Norwegian Institute of Public Health

Norway

Legislation for chemicals need to be revised

Dr Brett A. Lidbury

Associate Professor

NCEPH - The Australian National University

Australia

We need a centre like ECVAAM to support non-animal innovation for biomedical research.

Thomas Luechtefeld

CEO

ToxTrack Inc

United States

James Rathman

Professor

Ohio State University

USA

Yanitza Trosel

Researcher

Sunnybrook Research Institute

Canada

Start using mimic organ environments to test more basic system, then start increasing the complexity.

David Pamies

Research Associated

Univeristy of Lausanne

Switzerland

Paula Brügger

Professor coordinator of Ecological Justice Observatory

Federal University of Santa Catarina

Brazil

Niraj Kumar

Director

M.s

IND

Pandora Pound

Research Director

Safer Medicines Trust

UK

Brigitte Franke-Bray

Independent Consultant Pharmaceutical Medicine

Freelance

Switzerland

Pelin Candarliogu

Independent Consultant on the use of NAMS

3D and 3Rs

UK

Standardisation guidelines followed with a qualification framework for specific context of use and independent test centres that will evaluate and qualify different NAMs for regulatory acceptance

Dr Lilas Courtot

Science Manager

Animal Free Research UK

United-Kingdom

Francesca Pistollato

Senior Strategist - Biomedical science

HSI Europe

Italy

The transition towards human-relevant non-animal methods and models will help increase societal impact of funded research, in order to make scientific results really useful and translatable to human diseases and physiology.

Manuela Cassotta

Biologist Medical writer

OSA (Oltre la Sperimentazione Animale)

Italy

Dr. Christiane Hohensee

Subject specialist for Animal-free Research Methods

Federal Association ip People for Animal Rights

Germany

Dr. Vera Marashi

Senior Scientist

Association Against Animal Factories (VEREIN GEGEN TIERFABRIKEN, VGT)

Austria

Kathy Archibald

Chair

Safer Medicines Trust

UK

Elma Omeragic

Associate professor

University of Sarajevo

Bosnia and Herzegovina

Dr. Michelle Sinclair

Academic

Stanford Medical School

USA